Abstract Body

Presentation:

The implications of the results of Reprieve trial for Low and Middle Income Countries (LMICs), where the global burden of HIV, and the number of PWH who would be eligible to receive a statin based on the trial entry criteria are highest, are not clear. At face value it would seem that the potential to derive significant benefit from CVD morbidity and mortality reduction in PWH, should make the decision to adopt a pharma based primary CVD prevention public health strategy straightforward. On the other hand there are a number of challenges to implementing such a strategy in LMICS for policy makers, clinicians and health finance authorities, particularly in sub-Saharan Africa where the largest number of PWH live and resources are lowest. Whereas ASCVD is now the major cause of morbidity and mortality in PWH in many HICS, the same is not be true in most LMICS. Despite modelling estimates which suggest both a high incident ASCVD rate and large fraction of ASCVD attributable to HIV, observational (real world) data and clinical practice paint a different picture. AIDS related opportunistic infections still dominate the list of major causes of overall morbidity and mortality and amongst the non-HIV related causes of morbidity and mortality, CVD contributes a small proportion. Finally, amongst those with CVD, non-ischemic causes predominate. This may explain the relatively low LMICS MACE rate in the trial and significantly limits the justification for allocation of scarce resources to this important cause over others. Second, there are significant challenges to the use of conventional ASCVD risk scoring tools such as the Pooled Cohort Estimate (PCE) used in the trial to both HIV and non-HIV populations in LMICs. For example whereas the anticipated MACE rate based in part on study baseline PCE scores in the REPRIEVE trial was 12/1000, the observed MACE in the placebo arm was less than 3.5/1000 in participating LMICs and less than 2 in SSA. Such a low event rate would almost double the number of participants needed to treat to benefit from a statin, and by extension add significant costs to already constrained healthcare budgets. Given these and related challenges, a focus on healthy lifestyle and optimisation of traditional risk factors, is likely to remain the primary prevention strategy of choice in PWH living in LMICs for the near term future.